Anticoagulants offer no net advantages over antiplatelet agents in acute ischaemic stroke

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1400, 2003-01, pp. : 14-14

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Thrombolytic Agents for Acute Ischaemic Stroke Treatment: The Past, Present and Future

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 12, Iss. 2, 2013-04 ,pp. : 145-154

Bentham Science Publishers

Access to resources Recommend Favorite

Antiplatelet Agents and Anticoagulants: From Pharmacology to Clinical Practice

Current Pharmaceutical Design, Vol. 23, Iss. 9, 2017-04 ,pp. : 1279-1293

Bentham Science Publishers

Access to resources Recommend Favorite

Ongoing clinical trials of anti-platelet agents in the management of acute ischaemic coronary syndromes

By Straznicky I.T. Zambanini A. White H.D.

Expert Opinion on Investigational Drugs, Vol. 7, Iss. 5, 1998-05 ,pp. : 811-822

Informa Healthcare

Access to resources Recommend Favorite

Alteplase underused in acute ischaemic stroke

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 331, 2001-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Fibrinolytic treatment for acute ischaemic stroke

By Mazumdar Avi Derdeyn Colin P

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 3, 2006-02 ,pp. : 287-296

Informa Healthcare

Access to resources Recommend Favorite